Cyclacel Pharmaceuticals, Inc. (CYCC) Issues Quarterly Earnings Results
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) posted its quarterly earnings results on Wednesday. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, Bloomberg Earnings reports. Cyclacel Pharmaceuticals had a negative net margin of 1,128.13% and a negative return on equity of 65.31%.
Cyclacel Pharmaceuticals (CYCC) traded up 1.83% during trading on Friday, reaching $1.67. The company had a trading volume of 162,659 shares. The firm’s 50 day moving average price is $2.74 and its 200 day moving average price is $4.25. Cyclacel Pharmaceuticals has a 12-month low of $1.56 and a 12-month high of $10.90.
In other news, major shareholder Eastern Capital Ltd bought 850,000 shares of the stock in a transaction on Wednesday, July 19th. The stock was acquired at an average price of $2.00 per share, with a total value of $1,700,000.00. Following the acquisition, the insider now directly owns 2,167,261 shares in the company, valued at $4,334,522. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.00% of the stock is owned by corporate insiders.
Separately, Zacks Investment Research cut Cyclacel Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, April 26th.
COPYRIGHT VIOLATION NOTICE: This news story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/11/cyclacel-pharmaceuticals-inc-cycc-issues-quarterly-earnings-results.html.
Cyclacel Pharmaceuticals Company Profile
Cyclacel Pharmaceuticals, Inc operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors.
Receive News & Stock Ratings for Cyclacel Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.